Notre équipe

Dusty is an accomplished executive with 20 years of experience within the life sciences industry. Prior to joining CellCarta as Chief Executive Officer, Dusty served as an Operating Partner for Arsenal Capital Partners healthcare team. Further, Dusty has led several business transformations and related strategic acquisitions as CEO of Stirling Ultracold, President of Brooks Automation’s life sciences division (now Azenta) and Sr. Vice President of PerkinElmer’s Environmental Health division.

Dusty earned his bachelor’s degree, and graduated cum laude, from the University of Maryland, and he received his Master of Science degree from the University of Vermont.

Elliott Miller began his career at General Electric and Bank of America Merrill Lynch where he built expertise in operational excellence, strategy development, and M&A within a global environment. Most recently, he served as Senior Vice President of Finance at PPD and Thermo Fisher Scientific, leading the finance function for the Clinical Development Services Division and the Analytical Services Division — an industry-leading CRO and Labs Network. At CellCarta, Elliott oversees all aspects of financial strategy, supporting the company's continued growth and commitment to operational and scientific excellence.

Elliott received his undergraduate degree and MBA from Duke University and earned the Chartered Financial Analyst (CFA) designation.

Kristien Verhoeven is a seasoned life sciences executive with deep expertise in histopathology, genomics, and biomedical innovation. She is CellCarta’s Senior Vice President of the Histopathology, Genomics, and Logistics Business Units, where she leads strategic direction and operational oversight for these global business segments.

Kristien previously served as Head of Operations at HistoGeneX, where she played a key role in expanding and optimizing laboratory services. Before that, she was the Global Head of Implant Biology at Cochlear, where she led groundbreaking work in the development and clinical trials of a cochlear implant integrated with drug delivery — a first of its kind in the field.

Kristien holds a PhD in Medical Sciences, an MBA from the University of Antwerp, and completed executive education in Global Management at INSEAD.

As the Founder and CEO of Sampled, a spin out of Rutgers University serving the Biopharma with early stage, discovery and translation genomics, Robin brings valuable expertise in genomics, automation-driven solutions, and integrated service models for diagnostics and therapeutic research.

Prior to joining CellCarta, Robin held executive positions at Azenta Life Sciences (formerly Brooks Automation), where he led automation, consumables, and instrument business units, driving substantial revenue growth and transforming sample management technologies. Azenta acquired FluidX where Robin was a founder and owner, developing novel consumables and Instruments for Sample Management and High Throughput Screening.

He currently serves in the ISBER (International Society for Biological and Environmental Repositories) Outstanding New Product Award Task Force. His contributions to automation, sample storage innovation, and genomics technology development are reflected in multiple patents and industry recognitions.

Robin studied Applied Biology with Biochemistry/Microbiology at Anglia Ruskin University and obtained an Executive Certificate in Management and Leadership from the MIT Sloan School of Management.

Todd joined CellCarta in September 2020 as the leader of our quality, regulatory and government affairs team, overseeing the overall regulatory requirements on ISO, CAP /CLIA, GLP and GCLP, and assisting clients in defining their global regulatory pathways for their development and clinical programs.

Todd brings more than 26 years of combined experience in the biopharmaceutical, diagnostics, and food/nutrition businesses at Abbott. Todd has held a variety of technical and leadership roles in R&D, Operations, QA, and Regulatory Affairs. He has served on a number of boards and academic advisory positions including Regulatory Affairs Professional Society (RAPS), Lambs Farm, the International Life Sciences Institute, the Dean’s Advisory Board for the School of Pharmacy at Purdue University and as a Ford Scholar at Northwestern’s Kellogg School of Management.

Todd earned his bachelor’s degree in Pharmacy from Purdue University, a master’s degree in Engineering and Management Sciences from Northwestern University and a PhD in Pharmacy from the University of Illinois.

Mr. Christopher Ung has served in the companion diagnostics field since its inception and is one of the original pioneers of the personalized medicine field. He led the global commercialization efforts of the HercepTest™ and pharmDx EGFR companion diagnostic assays and continues to lead and implement global biomarker strategies for drug development projects. He has established several global companion diagnostic partnerships that have played a pivotal role in targeted therapy development and has set up CAP, CLIA laboratories in the US, Scotland, China, and Singapore.

Mr. Ung leads the development and execution of HistoGeneX’s strategic and business initiatives, leveraging the company’s solid tumor and anatomic pathology services. Prior to joining HistoGeneX, he was Vice President of Strategic Business & Operations at Quintiles, Chief Operating Officer for Targeted Molecular Diagnostics and Chairman of the Pathology Business Group at DAKO.

Dr. Ehab A. ElGabry is a physician-executive with over 25 years of experience combining clinical practice, diagnostic medicine, and translational research in oncology and precision diagnostics. He holds board certification in pathology, with fellowship training in breast pathology and cytopathology at the University of Florida after completing residency training at the Cleveland Clinic Foundation.

Dr. ElGabry began his professional journey as a urologic oncology surgeon — a foundation that gave him first-hand insight into patient care and the critical need for precise diagnostics.

Over his career, he has held key leadership roles in diagnostic medicine:

• As Head of CDx Pathology and Senior Medical Director at Roche Tissue Diagnostics, he led the development of both digital and manual scoring algorithms and contributed to multiple FDA-approved companion diagnostics including PDL-1.
• He then served as Chief Medical Officer at Akoya Biosciences, where he guided translational research and clinical adoption strategies of spatial phenotyping technologies.
• Most recently, he led the U.S. Medical Affairs Diagnostics team at Daiichi Sankyo, Inc. before joining CellCarta.

In addition to his corporate and clinical leadership, Dr. ElGabry has been active in advancing the scientific community: he served on the ASCO/CAP Task Force for Predictive Immuno‑Oncology Biomarkers and is a co-author of the ICI Predictive Biomarker Summit proceedings. He also served on the board of the Digital Pathology Association. He has authored more than 100 peer-reviewed publications and is a frequent speaker at national and international scientific workshops and conferences.

As CMO of CellCarta, Dr. ElGabry brings his deep expertise in pathology, diagnostics, translational research, and biomarker-driven precision oncology to help steer CellCarta’s mission to support global biopharma partners in developing next-generation therapies with robust, clinically validated diagnostic and biomarker programs.

Hayden Routledge joined CellCarta in 2021. Previously, he was the Corporate VP, Global Safety Assessment Sales at Charles River Laboratories. He has a PhD in neuroscience from the University of Glasgow.

Marcus Silva, JD, MBA began his career as a litigator in Southern California before successfully founding, building, and selling a home healthcare company in Greater Los Angeles. He subsequently built a career in healthcare across various commercial roles in in vitro diagnostics, medical devices, oncology pharmaceuticals, and clinical diagnostics, holding leadership responsibilities at Johnson & Johnson's Ortho Clinical Diagnostics, Becton Dickinson, Novartis — where he led CDx commercial launches for targeted therapies in breast cancer (PIQRAY) and lung cancer (TABRECTA) — and most recently was SVP of Commercial Growth at NeoGenomics with responsibility over clinical business development, strategic partnerships and business model innovation. He holds a JD from California Western School of Law and an MBA from Rutgers Business School.

Nancy El Sayegh joined CellCarta in 2019 and serves as the company’s Chief People & Legal Officer. In her role, Nancy helps CellCarta navigate complex business and legal matters while championing a people-first culture that supports the growth, engagement, and success of employees across the organization to achieve our customers’ goals. She provides strategic guidance across cybersecurity, privacy, labor and employment, intellectual property, and broader corporate governance matters, including being secretary for the board of directors. She also leads ESG and global facilities management, with a focus on optimizing physical infrastructure to enhance operational efficiency, sustainability, and employee well-being.

Louis is a seasoned technology leader with over 25 years of experience in enterprise architecture, application development, and life sciences. Prior to joining CellCarta, Louis held various leadership roles at LabCorp and Covance, where he led multiple software engineering teams and managed global technology initiatives. Louis oversees CellCarta’s global technology functions, leveraging his deep experience in laboratory processes, IT service management, and solution architecture to support business operations. He also leads CellCarta’s data engineering and data science teams to build robust data platforms, deliver cutting-edge visualization capabilities, and provide advanced analytics that enable sponsors to gain deeper insights and make more informed decisions.

Dusty is an accomplished executive with 20 years of experience within the life sciences industry. Prior to joining CellCarta as Chief Executive Officer, Dusty served as an Operating Partner for Arsenal Capital Partners healthcare team. Further, Dusty has led several business transformations and related strategic acquisitions as CEO of Stirling Ultracold, President of Brooks Automation’s life sciences division (now Azenta) and Sr. Vice President of PerkinElmer’s Environmental Health division.

Dusty earned his bachelor’s degree, and graduated cum laude, from the University of Maryland, and he received his Master of Science degree from the University of Vermont.

Dr. Rothman is the Sterling Professor of Cell Biology and Chair of the Department of Cell Biology at Yale University School of Medicine. His research discoveries have been recognized by the Nobel Prize in Physiology or Medicine in 2013, the Albert Lasker Award and the Kavli Prize for Neuroscience. Dr. Rothman has been elected to membership in the National Academy of Sciences and its Institute of Medicine. Previously, he served as Chief Scientist of General Electric Healthcare and has served on the advisory boards of Amersham PLC, Johnson & Johnson Scientific, and Merck Scientific. Dr. Rothman graduated with a B.A. from Yale College, attended Harvard Medical School and received a Ph.D. from Harvard University. He has previously been a professor at Stanford, Princeton, and Columbia Universities and at Memorial Sloan- Kettering Cancer Center, where he served as Vice Chairman of the Sloan-Kettering Institute.

Dr. Rothman is the Sterling Professor of Cell Biology and Chair of the Department of Cell Biology at Yale University School of Medicine. His research discoveries have been recognized by the Nobel Prize in Physiology or Medicine in 2013, the Albert Lasker Award and the Kavli Prize for Neuroscience. Dr. Rothman has been elected to membership in the National Academy of Sciences and its Institute of Medicine. Previously, he served as Chief Scientist of General Electric Healthcare and has served on the advisory boards of Amersham PLC, Johnson & Johnson Scientific, and Merck Scientific. Dr. Rothman graduated with a B.A. from Yale College, attended Harvard Medical School and received a Ph.D. from Harvard University. He has previously been a professor at Stanford, Princeton, and Columbia Universities and at Memorial Sloan- Kettering Cancer Center, where he served as Vice Chairman of the Sloan-Kettering Institute.

Dr. Gottlieb is a physician and served as the 23rd Commissioner of the U.S. Food and Drug Administration. Dr. Gottlieb’s work focuses on advancing public health through developing and implementing innovative approaches to improve medical outcomes, reshaping healthcare delivery, and expanding consumer choice and safety. He is currently a partner at the venture capital firm New Enterprise Associates; a resident fellow at the American Enterprise Institute; a contributor to CNBC; and a board member to Pfizer, Inc. and Illumina, Inc.

Under his leadership, the FDA advanced new frameworks for the safe and effective oversight of gene therapies, cell-based regenerative medicines, targeted drugs, digital health devices, and vaccine manufacturing. The agency implemented new reforms to standardize drug reviews and make historic improvements of post-market data collection and the use of real-world evidence. He promoted policies to reduce death and disease from tobacco, improve food innovation and safety, and aggressively confront addiction crises. The agency’s historic and prolific advances in new policy distinguished his tenure as the FDA’s commissioner, in addition to a record-setting number of approvals of novel drugs, medical devices, and generic medicines.

Previously, Dr. Gottlieb served as the FDA’s Deputy Commissioner for Medical and Scientific Affairs and before that, as a Senior Adviser to the Administrator of the Centers for Medicare and Medicaid Services, where he helped advance policies to improve healthcare quality and promote the effective use of new medical technologies. Dr. Gottlieb was a practicing hospitalist and a Clinical Assistant Professor at the New York University School of Medicine. He is an elected member of the National Academy of Medicine.

George Demetri, MD, FASCO has dedicated his career to translational research aimed at understanding and treating precisely-defined subsets of cancers. He was a pioneer in the development of imatinib (Gleevec®), the first cancer therapy targeting gastrointestinal stromal tumor (GIST) as a molecularly defined subset of sarcoma. Subsequently, his work has contributed to the U.S. FDA and worldwide regulatory approvals of several other “smart drugs” for cancer, including sunitinib (Sutent®) and regorafenib (Stivarga®) for GIST, tazemetostat (Tazverik®) for epithelioid sarcomas, as well as pazopanib (Votrient®) and trabectedin (Yondelis®) for other sarcomas. In a related contribution, Dr. Demetri served on the Scientific Advisory Board for Plexxikon to help develop the first mutant BRAF inhibitor, vemurafenib (Zelboraf®), a mutation-targeted therapy for a subset of melanomas. Most recently, he helped start Blueprint Medicines in Cambridge, MA, which recently announced the U.S. FDA approval of avapritinib (Ayvakit®) for a mutationally-defined subset of GIST.

He received his undergraduate degree in Biochemistry from Harvard College, then was a research fellow at the Universite of Besancon, France before receiving his medical degree from Stanford University School of Medicine. Subsequently, he completed his residency and became Chief Residency in Internal Medicine at the University of Washington Medical Center in Seattle before training as a fellow in Medical Oncology at the Dana-Farber Cancer Institute and Harvard Medical School, where he has served as an Attending Physician since 1989.

Dr. Demetri is a Professor of Medicine at the Harvard Medical School (HMS), where he is co-Director of the Ludwig Center at Harvard and a co-director of the HMS post-graduate course entitled “High Impact Cancer Research: Cancer Biology and Therapeutics”. He also teaches a Harvard College Freshman Seminar on the Scientific, Ethical and Humanistic Aspects of Cancer. He has served on the Board of Directors of the American Association for Cancer Research (AACR) and now chairs the AACR Science Policy and Government Affairs Committee. Dr. Demetri was a founding director of the annual AACR special workshop on Translational Cancer Research for the Basic Scientist. He also serves as a member of the Board of Directors for Blueprint Medicines and Translate Bio, both in Cambridge Massachusetts.

Dr. Powles is a Clinical Professor of Genitourinary Oncology and the lead for solid tumor research at Barts Cancer Institute in the United Kingdom. His work focuses on a spectrum of clinical studies from Phase I to randomized Phase III, with the majority of the studies being translational Phase II investigating novel targeted and immune therapies. Alongside these trials, Dr. Powles’ research focuses on correlation of novel biomarkers and aims to define markers that are of prognostic value and can predict response or resistance to therapy. Dr. Powles has written in over 100 peer review papers in this area and has received grant income from national and international funding bodies. He graduated from St. Bartholomew’s Medical School, London in 1996, and completed his post-graduate training in oncology in 2005, receiving an MD from the University of London in 2006.

Charles L. Sawyers received a BA from Princeton University in 1981 and an MD from Johns Hopkins University School of Medicine in 1985 and completed his internal medicine residency at UCSF. He became a Howard Hughes Medical Institute Investigator in 2002 while at UCLA and then moved to the Memorial Sloan Kettering Cancer Center in 2006 where he currently serves as the Chair of the Human Oncology and Pathogenesis Program.

Sawyers studies mechanisms of cancer drug resistance with an eye toward developing novel therapies. He co-discovered the antiandrogen drug enzalutamide (Xtandi®) that was approved by the FDA in 2012 for treatment of advanced prostate cancer. He shared the 2009 Lasker-DeBakey Clinical Medical Research Award for the development of the ABL kinase inhibitor imatinib for patients with chronic myeloid leukemia and the second generation ABL inhibitor dasatinib to overcome imatinib resistance. He received the 2013 Breakthrough Prize in Life Sciences, the 2013 Taubman Prize for Excellence in Translational Medical Science and the 2015 BBVA Knowledge Award in Biomedicine.

Sawyers is a member of the National Academy of Sciences, the National Academy of Medicine (formerly IOM) and the American Academy of Arts and Sciences. He is the past President of the American Association for Cancer Research (AACR) and the American Society of Clinical Investigation (ASCI), was appointed to the National Cancer Advisory Board by President Obama and has served on the Board of Directors of Novartis since 2013. He also serves as Steering Committee Chair of the AACR Project GENIE, an international consortium of cancer centers who share genomic and clinical data from patients treated at their respective clinical sites.

Carl June is the Richard W. Vague Professor in Immunotherapy in the Department of Pathology and Laboratory Medicine. He is currently Director of the Center for Cellular Immunotherapies at the Perelman School of Medicine, and Director of the Parker Institute for Cancer Immunotherapy at the University of Pennsylvania. He is a graduate of the Naval Academy in Annapolis, and Baylor College of Medicine in Houston, 1979. He received his graduate training in immunology and malaria with Dr. Paul-Henri Lambert at the World Health Organization, Geneva, Switzerland from 1978-79, and his post-doctoral training in transplantation biology with E. Donnell Thomas and John Hansen at the Fred Hutchinson Cancer Research Center in Seattle from 1983 – 1986. He is board certified in Internal Medicine and Medical Oncology. He maintains a research laboratory that studies various mechanisms of lymphocyte activation that relate to immune tolerance and adoptive immunotherapy for cancer and chronic infection. In 2011, his research team published findings detailing a new therapy in which patients with refractory and relapsed chronic lymphocytic leukemia were treated with genetically engineered versions of their own T cells. The treatment has now been used with promising results to treat children with refractory acute lymphoblastic leukemia. He has published more than 350 manuscripts and is the recipient of numerous prizes and honors, including election to the Institute of Medicine in 2012 and the American Academy of Arts and Sciences in 2014, the William B Coley award, the Richard V Smalley Memorial Award from the Society for Immunotherapy of Cancer, the AACR-CRI Lloyd J. Old Award in Cancer Immunology, the Philadelphia Award in 2012, the Taubman Prize for Excellence in Translational Medical Science in 2014 (shared w S. Grupp, B. Levine, D. Porter), the Paul Ehrlich and Ludwig Darmstaedter Prize (shared w J. Allison), the Novartis Prize in Immunology (shared w Z. Eshaar and S. Rosenberg), the Karl Landsteiner Memorial award, the Debrecen Award and a lifetime achievement award from the Leukemia and Lymphoma Society.

Rupert served as Executive Vice President and President, Research and Early Development for Bristol Myers Squibb (BMS). He joined BMS with its acquisition of Celgene in 2019. In this role, he led Research and Early Development, overseeing the advancement of promising programs, technologies and assets across all therapeutic areas, from discovery through proof-of-concept. He also worked closely with Business Development to identify external sources of innovation. In addition, he served as the executive sponsor of the Organization for Latino Achievement (OLA) People and Business Resource Group and the Bristol Myers Squibb STEM Council.

Rupert joined BMS from Celgene, where he served as president of the company’s Research and Early Development organization. Prior to joining Celgene in 2015, Rupert spent ten years at Merck, where he was responsible for numerous drug development programs and held leadership roles in the company’s Early Development, Discovery Sciences, Drug Discovery and Informatics groups, as well as its respiratory and immunology franchise. Prior to his time at Merck, he spent five years at GlaxoSmithKline involved in drug discovery, experimental medicine and early clinical development of therapeutics for respiratory and immune diseases.

Rupert graduated from Oxford University in the United Kingdom with degrees in physiological sciences (MA), clinical medicine (BM, BCh) and a doctor of philosophy (DPhil) in molecular immunology. He is an elected fellow of the Royal College of Physicians.